YOUR SEARCH FOR Text 261 RESULTS
41 of Total
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Canc
Press Release View all news Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D
42 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
Press Release View all news Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs July 29, 2025 at 7:00
43 of Total
Media Contact | Incyte
Media Contact Name Email Subject Comments Leave this field blank For Media Inquiries media@incyte.com
44 of Total
Press Releases | Incyte
Press Releases The information contained in press releases should be considered accurate only as of the date of the press release. We disclaim any
45 of Total
Resources | Incyte
Resources Investor Email Alerts RSS Feeds Investor FAQs Subscribe to Email Alerts To opt-in for investor email alerts, please enter your email
47 of Total
Stock information | Incyte
Stock information Stock Quote & Chart Historical Lookup Analyst Coverage Stock Quote Change Volume Today's Open Previous Close Today's
48 of Total
Incyte Stories from Researchers and Scientists | Incyte.com
Innovation with the Incyte Ingenuity Awards . View Story Our Global Responsibility: By the Numbers . View Story Incyte Gets Involved . View Story
49 of Total
Incyte Stories from Researchers and Scientists | Incyte.com
Understanding Hidradenitis Suppurativa (HS) . View Story The Science Within the Skin . View Story Understanding DLBCL . View Story Solve On . Stories
50 of Total
2023 Year in Review | Incyte Stories
February 1, 2024 2023: How We Continue to Solve On . For Patients In 2023, we progressed our mission to Solve On . for patients around the world and